Tags

Type your tag names separated by a space and hit enter

Inhibition of cyclic gonadotropin secretion by endogenous human prolactin.
Am J Obstet Gynecol. 1975 Feb 01; 121(3):375-9.AJ

Abstract

The resumption of cyclic uterine bleeding reportedly accompanies the use of human prolactin (HPRL)-suppressing agents in postpill galactorrhea-amenorrhea. In this laboratory, HPRL suppression with L-dopa was variable and short lived. Basal plasma HPRL levels were elevated before and after as much as five months of therapy. Galactorrhea persisted and mean gonadotropin concentrations were subnormal. An immediate and sustained attenuation of HPRL secretion (less than 200 per cent) followed the use of 2-Br-alpha-ergocryptine (CB-154). Cyclic gonadotropin secretion resumed and was accompanied by ovulation and, in one instance, pregnancy. The cessation of galactorrhea was positively correlated with the rise in the daily concentration of 17 beta-estradiol. Cyclic postovulatory menstruation continued after the cessation of CB-154 treatment. HPRL levels remained normal. The daily patterns of human follicle-stimulating hormone (HFSH) and human tuteinizing hormone (HLH) secretion created by the suppression of HPRL displayed an inherent rhythmicity identical to that observed at the time of menarche. The inhibitory effects of HPRL appeared directed at cyclic rather than tonic gonadotropin secretion. At the same time, diminished ovarian estrogen production seemed to increase mammary gland sensitivity to HPRL, leading to lactation. One may postulate, therefore, that the ingestion of sex steroids is associated with an over-all suppression of endogenous cyclic and, to a lesser extent, tonic gonadotropin secretion secondary to which ovarian function is attenuated. Without physiologic concentration of circulating estrogen, HPRL induces mammary alveolar function with the production of a milklike secretion.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

1115151

Citation

Tyson, J E., et al. "Inhibition of Cyclic Gonadotropin Secretion By Endogenous Human Prolactin." American Journal of Obstetrics and Gynecology, vol. 121, no. 3, 1975, pp. 375-9.
Tyson JE, Khojandi M, Huth J, et al. Inhibition of cyclic gonadotropin secretion by endogenous human prolactin. Am J Obstet Gynecol. 1975;121(3):375-9.
Tyson, J. E., Khojandi, M., Huth, J., Smith, B., & Thomas, P. (1975). Inhibition of cyclic gonadotropin secretion by endogenous human prolactin. American Journal of Obstetrics and Gynecology, 121(3), 375-9.
Tyson JE, et al. Inhibition of Cyclic Gonadotropin Secretion By Endogenous Human Prolactin. Am J Obstet Gynecol. 1975 Feb 1;121(3):375-9. PubMed PMID: 1115151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibition of cyclic gonadotropin secretion by endogenous human prolactin. AU - Tyson,J E, AU - Khojandi,M, AU - Huth,J, AU - Smith,B, AU - Thomas,P, PY - 1975/2/1/pubmed PY - 1975/2/1/medline PY - 1975/2/1/entrez KW - Alkaloids KW - Amenorrhea--etiology KW - Amines KW - Biology KW - Catecholamines KW - Central Nervous System Effects KW - Clinical Research KW - Diseases KW - Endocrine System KW - Ergot Alkaloids--therapeutic use KW - Estradiol--analysis KW - Estrogens KW - Follicle Stimulating Hormone--analysis KW - Galactorrhea--etiology KW - Gonadotropins KW - Gonadotropins, Pituitary KW - Hormones KW - Ingredients And Chemicals KW - Luteinizing Hormone--analysis KW - Menstruation Disorders KW - Oral Contraceptives KW - Organic Chemicals KW - Physiology KW - Pituitary Hormones KW - Prolactin--analysis KW - Puerperal Disorders KW - Research Methodology SP - 375 EP - 9 JF - American journal of obstetrics and gynecology JO - Am J Obstet Gynecol VL - 121 IS - 3 N2 - The resumption of cyclic uterine bleeding reportedly accompanies the use of human prolactin (HPRL)-suppressing agents in postpill galactorrhea-amenorrhea. In this laboratory, HPRL suppression with L-dopa was variable and short lived. Basal plasma HPRL levels were elevated before and after as much as five months of therapy. Galactorrhea persisted and mean gonadotropin concentrations were subnormal. An immediate and sustained attenuation of HPRL secretion (less than 200 per cent) followed the use of 2-Br-alpha-ergocryptine (CB-154). Cyclic gonadotropin secretion resumed and was accompanied by ovulation and, in one instance, pregnancy. The cessation of galactorrhea was positively correlated with the rise in the daily concentration of 17 beta-estradiol. Cyclic postovulatory menstruation continued after the cessation of CB-154 treatment. HPRL levels remained normal. The daily patterns of human follicle-stimulating hormone (HFSH) and human tuteinizing hormone (HLH) secretion created by the suppression of HPRL displayed an inherent rhythmicity identical to that observed at the time of menarche. The inhibitory effects of HPRL appeared directed at cyclic rather than tonic gonadotropin secretion. At the same time, diminished ovarian estrogen production seemed to increase mammary gland sensitivity to HPRL, leading to lactation. One may postulate, therefore, that the ingestion of sex steroids is associated with an over-all suppression of endogenous cyclic and, to a lesser extent, tonic gonadotropin secretion secondary to which ovarian function is attenuated. Without physiologic concentration of circulating estrogen, HPRL induces mammary alveolar function with the production of a milklike secretion. SN - 0002-9378 UR - https://www.unboundmedicine.com/medline/citation/1115151/Inhibition_of_cyclic_gonadotropin_secretion_by_endogenous_human_prolactin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-9378(75)90015-0 DB - PRIME DP - Unbound Medicine ER -